Sana Biotechnology, Inc. (SANA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Overview - The company has streamlined its pipeline to focus on two key products: SC451, a T1D islet cell product, and SG293, an in vivo CAR T product [1] Group 1: Type 1 Diabetes (T1D) - Type 1 diabetes is a well-understood disease characterized by the immune system attacking pancreatic beta cells, which are responsible for insulin production [1] - Historically, prior to insulin therapy, T1D was a fatal condition leading to rapid death within months [1]